Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249634 | 0.95 | EPHX2 (0.43) | HDAC6HDAC1HDAC2EPHX2CA14 | |
| SCHEMBL23113130 | 0.93 | EPHX2 (0.45) | HDAC6HDAC1HDAC2EPHX2LMNA | |
| SCHEMBL28909803 | 0.93 | EPHX2 (0.45) | HDAC6HDAC1HDAC2EPHX2LMNA | |
| SCHEMBL8360181 | 0.93 | EPHX2 (0.45) | HDAC6HDAC1HDAC2EPHX2LMNA | |
| SCHEMBL10646993 | 0.89 | KDM4A (0.40) | HDAC6HDAC1HDAC2EPHX2CA14 | |
| SCHEMBL381146 | 0.89 | HDAC6 (0.39) | HDAC6HDAC1HDAC2CA14TSHR | |
| Succinic Acid SCHEMBL28315096 | 0.87 | PHF8 (0.39) | HDAC6HDAC1HDAC2CA14LMNA | |
| SCHEMBL734219 | 0.86 | HDAC6 (0.38) | HDAC6HDAC1HDAC2CA14BUB1 | |
| SCHEMBL6256081 | 0.85 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14BUB1 | |
| SCHEMBL9219474 | 0.85 | HDAC6 (0.40) | HDAC6HDAC1HDAC2CA14BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6342201-B1 | COMPLEXES WHICH ENRICH ARTERIOSCLEROTIC PLAQUE AND ARE PREFERENTIALLY SUITED FOR NON-INVASIVE DIAGNOSIS OF ARTERIOSCLEROSIS | INSTITUT FOR DIAGNOSTIKFORSCHUNG GMBH AN DER FREIEN UNIVERSITAT (DE) | 2002-01-29 | — | — | US | claimed |
| CN-122055156-A | (R) -N-ethyl-5-fluoro-N-isopropyl-2- ((5- (2- (6- ((2-methoxyethyl) (methyl) amino) -2-methyl-hex-3-yl) -2, 6-diazaspiro [3.4] oct-6-yl) -1,2, 4-triazin-6-yl) oxy) benzamide, formulations and dosing regimens for treating cancer | 詹森药业有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025082444-A2 | (R) -N-ETHYL-5-FLUORO-N-ISOPROPYL-2- ( (5- (2- (6- ( (2-METHOXYETHYL) (METHYL) AMINO) -2-METHYLHEXAN-3-YL) -2, 6-DIAZASPIRO [3.4] OCTAN-6-YL) -1, 2, 4-TRIAZIN-6-YL) OXY) BENZAMIDE, FORMULATIONS AND DOSAGE REGIMENS THEREOF, FOR USE IN TREATING CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-24 | — | — | WO | disclosed |
| EP-0215942-B1 | POLYNUCLEOTIDE ASSAY REAGENT AND METHOD | ANTIVIRALS INC (US) | 1995-07-12 | — | — | EP | disclosed |
| EP-0639582-A2 | Polynucleotide assay reagent and method | ANTIVIRALS INC. (US) | 1995-02-22 | — | — | EP | disclosed |
| CN-1026892-C | New amino acid derivatives, process for preparation thereof and pharmaceutical composition comprising same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-12-07 | — | — | CN | disclosed |
| EP-0300189-B1 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-11-02 | — | — | EP | disclosed |
| US-5223489-A | Treatment of ypertension and heart failure | UJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-06-29 | — | — | US | disclosed |
| US-5217866-A | Polynucleotide assay reagent and method | ANTI-GENE DEVELOPMENT GROUP (US) | 1993-06-08 | — | — | US | disclosed |
| US-5142048-A | Enzyme inhibitor; carbamoyl group-containing acids | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
| CN-1030411-A | New amino acid derivatives, its preparation method and contain its pharmaceutical composition | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-01-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | HDAC6 1225/4885HDAC1 1615/4885HDAC2 3013/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | HDAC6 563/4885HDAC1 881/4885HDAC2 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.